Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

Related Keywords

Texas ,United States ,Houston ,Naveen Pemmaraju ,Department Of Leukemia ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Navitoclax ,Navitoclax Plus Ruxolotinib ,Myelofibrosis ,Cash ,Ash Annual Meeting ,Transform 1 Study ,D ,Md Anderson ,